Addenbrooke's Hospital-ko ikertzaileekin lankidetzan egindako argitalpenak (26)

2023

  1. ESGO/ESTRO quality indicators for radiation therapy of cervical cancer

    International Journal of Gynecological Cancer, Vol. 33, Núm. 6, pp. 862-875

  2. ESGO/ESTRO quality indicators for radiation therapy of cervical cancer

    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, Vol. 183, pp. 109589

  3. Protective ileostomy creation after anterior resection of the rectum: Shared decision-making or still subjective?

    Colorectal Disease, Vol. 25, Núm. 4, pp. 647-659

  4. Uncertainties and controversies in axillary management of patients with breast cancer

    Cancer Treatment Reviews, Vol. 117

2022

  1. Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, Núm. 1, pp. 24-33

  2. Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, Núm. 7, pp. 483-494

  3. Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapy

    Breast, Vol. 63, pp. 123-139

  4. Text mining and word embedding for classification of decision making variables in breast cancer surgery

    European Journal of Surgical Oncology, Vol. 48, Núm. 7, pp. 1503-1509

  5. Validation of the OAKS prognostic model for acute kidney injury after gastrointestinal surgery

    BJS Open, Vol. 6, Núm. 1

2021

  1. Elective Cancer Surgery in COVID-19-Free Surgical Pathways during the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study

    Journal of Clinical Oncology, Vol. 39, Núm. 1, pp. 66-78

  2. Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma

    Future Oncology, Vol. 17, Núm. 11, pp. 1295-1310

  3. Preoperative nasopharyngeal swab testing and postoperative pulmonary complications in patients undergoing elective surgery during the SARS-CoV-2 pandemic

    British Journal of Surgery, Vol. 108, Núm. 1, pp. 88-96

  4. Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study

    Journal of Hematology and Oncology

  5. The Impact of the COVID-19 Pandemic on Surgical Management of Breast Cancer: Global Trends and Future Perspectives

    Oncologist, Vol. 26, Núm. 1, pp. e66-e77

2020

  1. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial

    The Lancet Haematology, Vol. 7, Núm. 7, pp. e511-e522

2018

  1. Risk factors for unfavourable postoperative outcome in patients with Crohn's disease undergoing right hemicolectomy or ileocaecal resection. An international audit by ESCP and S-ECCO

    Colorectal Disease, Vol. 20, Núm. 3, pp. 219-227

2017

  1. Erratum to: Meta-analysis of tumour burden in pre-operative axillary ultrasound positive and negative breast cancer patients (Breast Cancer Research and Treatment, (2017), 166, 2, (329-336), 10.1007/s10549-017-4405-3)

    Breast Cancer Research and Treatment

  2. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials

    The Lancet Oncology, Vol. 18, Núm. 9, pp. 1159-1171

  3. Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation

    Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380

  4. Meta-analysis of tumour burden in pre-operative axillary ultrasound positive and negative breast cancer patients

    Breast Cancer Research and Treatment, Vol. 166, Núm. 2, pp. 329-336